Hemophilia A Treatment Sector: Growth Drivers and Challenges
Growth Drivers
Rising Instances of Genetic Disorders to Boost the Market Growth
The cases of genetic disorders such as hemophilia have been growing significantly in the past few years and are estimated to grow further in the coming years. According to the National Hemophilia Foundation, Hemophilia A occurs in 1 out of 5,000 live male births in the United States. Additionally, hemophilia A is four times more common than hemophilia B. About 20,000 people in the United States are estimated to have hemophilia. Globally, around 400,000 people are predicted to be hemophilic. The report mentioned that approximately 75% of people with hemophilia do not receive proper treatment. On the back of these statistics, the market for hemophilia A drugs is anticipated to grow over the forecast period.
Challenges
High Cost of Treatment for Hemophilia A to Restrict the Market Growth
The high costs associated with the drugs as well as the therapies available for hemophilia A treatment is predicted to make them unaffordable for a large section of the society, specially people belonging to the low- and middle-income countries. On the basis of this factor, the hemophilia A drugs market is estimated to observe limited growth in coming years.
